Background:To explore the optimal timing of vitrectomy for vitreous hemorrhage in the patients with proliferative diabetic retinopathy (PDR).Method:Seventy-six PDR patients (85 eyes) who were diagnosed with vitreous hemorrhage and received vitrectomy were retrospectively enrolled into this study. The patients were categorized into 4 groups based on the timing of surgical intervention after the occurrence of hemorrhage, namely Group 1 (less than 15 days, with 28 eyes of 27 patients), Group 2 (15~30 days, with 29 eyes of 27 patients), Group 3 (30~90 days, with 14 eyes of 11 patients) and Group 4 (>90 days, with 14 eyes of 11 patients). Best corrected visual acuity (BCVA) and central macular thickness (CMT) from OCT before and at 1 mo and 3 mo after operation were collected as the main outcomes. The postoperative complications were also reported.Result: 1) BCVA (logMAR): the mean pre-operation BCVA was not significantly different among the 4 groups (P=0.139), while the mean post-operation BCVA was significantly worse in groups with longer gap between the vitreous bleeding and the vitrectomy, both at 1m and 3m after surgery (P=0.043; P<0.001). 2) CMT(μm): Although CMT was unavailable to measure in most included eyes before surgery, the mean CMT was significantly thicker in groups with postponed surgical intervention both at 1-month (P=0.001) and at 3-month (P=0.006) after surgery. 3) Complications: No severe complications were spotted in early vitrectomy groups (Group 1 and Group 2) during the follow-up period. At 3 months after the operation, three cases of ocular hypertension and another case of neovascular glaucoma in Group 3 and 4 cases of ocular hypertension and another 3 cases of neovascular glaucoma in Group 4 were observed. Conclusion: Early vitrectomy is more effective in improving BCVA and decreasing CMT in the PDR patients with vitreous hemorrhage. Moreover, the post-operation complications were spotted less in early vitrectomy groups. Thus we suggested that vitrectomy should be performed early and better within one month after the onset of vitreous hemorrhage in PDR patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.